Dose‐limiting effects in rodents were related to the pharmacology of VIT‐2763 (restricted iron uptake) and resulting iron deficiency anemia and subsequent secondary effects thereof.32 In a mouse model of NTDT, VIT‐2763 decreased serum iron levels, ameliorated anemia and improved ineffective erythropoiesis.32 Thus, limiting iron availability for erythropoiesis via ferroportin inhibition is a potential approach to treating NTDT.33 Here, SLC40A1 is linked to anemia.